Molecular imaging and the failing heart: through the looking glass.
Mann
Douglas L
DL
D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D002232:Carbocyanines; D002317:Cardiovascular Agents / Q000494:pharmacology; D004359:Drug Therapy, Combination; D004452:Echocardiography; D024022:Fibrillar Collagens / Q000378:metabolism; D005347:Fibroblasts / Q000000981:diagnostic imaging / Q000187:drug effects; D005355:Fibrosis; D006333:Heart Failure / Q000000981:diagnostic imaging* / Q000503:physiopathology / Q000517:prevention & control; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000494:pharmacology; D009203:Myocardial Infarction / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000503:physiopathology; D009206:Myocardium / Q000378:metabolism / Q000473:pathology*; D009842:Oligopeptides; D011237:Predictive Value of Tests; D013667:Technetium; D015899:Tomography, Emission-Computed, Single-Photon; D016277:Ventricular Function, Left / Q000187:drug effects; D020257:Ventricular Remodeling / Q000187:drug effects
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; C098793:CY5.5 cyanine dye; D002232:Carbocyanines; D002317:Cardiovascular Agents; D024022:Fibrillar Collagens; D000451:Mineralocorticoid Receptor Antagonists; D009842:Oligopeptides; D013667:Technetium; C047981:arginyl-glycyl-aspartic acid